Spravato® (esketamine) differs from traditional antidepressants in both its mechanism of action and speed of symptom relief. Most conventional antidepressants, such as SSRIs and SNRIs, work by gradually increasing neurotransmitters like serotonin, norepinephrine, or dopamine in the brain. These medications typically take several weeks to produce noticeable improvements in mood. However, Spravato® nasal spray targets the brain’s glutamate system, which plays a key role in neural communication and synaptic plasticity. By acting on NMDA receptors, Spravato® helps restore connections between brain cells that may be disrupted in people with treatment-resistant depression, allowing some patients to experience relief much faster than with traditional medications.
Another important difference is how the medication is administered and monitored. Traditional antidepressants are usually taken daily as oral medications at home, while Spravato® is delivered as a nasal spray in a certified clinical setting under medical supervision. Patients at a Spravato® treatment center for mental health remain in the clinic for monitoring after each dose to ensure safety and manage potential side effects such as dizziness or dissociation. Because of this structured treatment process, Spravato® nasal spray is typically used for individuals who have not responded adequately to other antidepressant therapies, offering a specialized option for people struggling with persistent or treatment-resistant depression.
How Spravato® Nasal Spray Differs From Traditional SSRIs and SNRIs
While both Spravato® and traditional antidepressants are used to treat depression, they differ significantly in how they work, how quickly they act, and how they are administered.
- Different Brain Chemistry Targeted: SSRIs and SNRIs primarily affect serotonin and norepinephrine levels, while Spravato® targets the glutamate system, which plays a major role in neural communication and brain plasticity.
- Faster Potential Relief: Traditional antidepressants often take several weeks to improve symptoms, whereas Spravato® may help reduce depressive symptoms more rapidly for some individuals with treatment-resistant depression.
- Designed for Treatment-Resistant Depression: Spravato® is typically prescribed for people who have not responded adequately to at least two other antidepressant medications, while SSRIs and SNRIs are commonly used as first-line treatments.
- Different Method of Administration: SSRIs and SNRIs are taken orally at home, usually once per day, while Spravato® is administered as a nasal spray in a certified healthcare setting under professional supervision.
- Structured Monitoring Requirements: Because Spravato® can cause temporary side effects such as sedation or dissociation, patients are monitored in the clinic for a period after treatment, which is not required with standard oral antidepressants.
The Science Behind Esketamine and Rapid-Acting Antidepressants
Esketamine, the active ingredient in Spravato®, represents a newer class of rapid-acting antidepressants that work differently from traditional medications used to treat depression. Instead of primarily affecting serotonin or norepinephrine levels, esketamine targets the brain’s glutamate system, the most abundant excitatory neurotransmitter network in the brain.
Specifically, esketamine blocks NMDA (N-methyl-D-aspartate) receptors, which leads to a cascade of neurochemical changes that increase glutamate signaling. This process stimulates AMPA receptors and helps promote the release of brain-derived neurotrophic factor (BDNF), a protein associated with the growth and strengthening of neural connections.
These changes are important because research suggests that major depressive disorder is linked to disrupted neural connectivity and reduced synaptic plasticity in key areas of the brain involved in mood regulation, such as the prefrontal cortex. By rapidly enhancing synaptic communication and encouraging the formation of new neural pathways, the benefits of ketamine therapy for mental health include restoring healthy brain activity more quickly than conventional antidepressants. This mechanism is believed to be a key reason why some patients experience improvements in depressive symptoms within hours or days rather than the several weeks often required for traditional antidepressant medications.
Mental Health Treatment That Works
Call 949-625-0564What our customers are saying
Who Is a Candidate for Spravato® Nasal Spray Treatment?
Spravato® nasal spray is prescribed for individuals with certain types of depression who have not found sufficient relief with standard antidepressant medications.
- Adults With Treatment-Resistant Depression: Individuals who have tried at least two different antidepressant medications without significant improvement in their symptoms.
- People Experiencing Persistent Major Depressive Disorder: Those who continue to struggle with severe depressive symptoms despite ongoing treatment with medication or therapy.
- Patients With Major Depressive Disorder and Suicidal Thoughts or Behaviors: In some clinical settings, Spravato® for depression treatment may be used as part of a supervised plan for individuals experiencing acute suicidal ideation.
- Individuals Able to Attend In-Clinic Treatment Sessions: Because Spravato® must be administered in a certified healthcare setting, candidates must be able to attend scheduled treatment appointments and remain for post-dose monitoring.
- Patients Who Can Combine Spravato® With an Oral Antidepressant: The treatment is typically prescribed alongside a traditional antidepressant as part of a comprehensive care plan.
How Often Is Spravato® Nasal Spray Administered?
Spravato® nasal spray is administered on a structured treatment schedule that begins with a more frequent dosing phase and gradually transitions to maintenance treatment. During the initial induction phase, which typically lasts the first four weeks, patients receive Spravato® treatments twice per week in a certified clinical setting. This early phase is designed to help rapidly reduce depressive symptoms while clinicians closely monitor the patient’s response to the medication and adjust the treatment plan if needed.
After the first month, treatment usually moves into a maintenance phase, where the frequency of dosing may decrease depending on how well the patient responds. Many patients receive Spravato® once per week for several weeks, followed by once every two weeks as symptoms stabilize. Because the medication can cause temporary side effects such as dizziness, sedation, or dissociation, each session requires in-clinic administration with monitoring for at least two hours afterward to ensure safety and effectiveness. The exact schedule may vary based on individual needs and clinical guidance.
Key Takeaways on Spravato Nasal Spray
- Spravato® offers a new approach to treating depression by targeting the brain’s glutamate system rather than the serotonin or norepinephrine pathways used by traditional antidepressants.
- It may work faster than conventional medications, with some patients experiencing symptom relief within hours or days instead of waiting several weeks.
- Spravato® is typically prescribed for treatment-resistant depression, meaning it is intended for individuals who have not improved after trying at least two other antidepressant medications.
- The medication is administered as a nasal spray in a certified healthcare setting, where patients are monitored after each dose to ensure safety and manage possible side effects.
- Treatment follows a structured schedule, beginning with twice-weekly sessions during the initial phase and transitioning to less frequent maintenance treatments as symptoms improve.
If you or someone you know is struggling with treatment-resistant depression, consider reaching out to Moment of Clarity to learn about the benefits of Spravato® nasal spray. This innovative treatment is designed to assist adults who haven’t found relief from traditional antidepressant therapies. The use of Spravato® is guided by a team of experienced professionals, ensuring that patients receive safe and effective care throughout the process.
To learn more about how this treatment could help you or your loved one, please call 949-625-0564 for more information and support.
Resources
- Keck School of Medicine of USC – Spravato (Esketamine Nasal Spray)
- Mayo Clinic – Esketamine (nasal route)
- Johns Hopkins Medicine – Esketamine for Treatment-Resistant Depression
